Skip to main content

Recent News

Save the date! We are covering #EULAR24 ! Will we see you there? https://t.co/aMGYnPxlXh
Dr. John Cush @RheumNow (  View Tweet)
No Link Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance Annals of Internal Medicine reports a study of more than 75,000 persons screened for MGUS and found no association between AIRD and MGUS. https://t.co/F8diWbUYPf https://t.co/M53Dgphcge
Dr. John Cush @RheumNow (  View Tweet)
Australian multicenter KARAOKE RCT of 262 adults w/ Knee OA (w/ MRI effusion/synovitis) Rx w/ placebo vs , 2 g/d of krill oil showed no significant benefit in pain VAS score, −19.9 [krill oil] vs −20.2 [placebo]. https://t.co/aeNcVM0p8J https://t.co/2PR0PG6eWj
Dr. John Cush @RheumNow (  View Tweet)
Upside/Downside of Steroids in Lupus Nephritis A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis (LN) demonstrates both the benefits and harms to early glucocorticoid (GC) regimens on lupus outcomes. https://t.co/T88365IT9r https://t.co/xe5AmErLy2
Dr. John Cush @RheumNow (  View Tweet)
384 Psoriasis pts followed mean 33 mos, 56 (14.6%) developed new-onset PsA. 311/384 (81%) had arthralgia (subclinical PsA) & 9.4% got PsA within 12 mos (23% by 36%). Subclinical more likely than PSO to get PsA (OR 11.7) https://t.co/9t41cjROwW https://t.co/9AelBwoRzs
Dr. John Cush @RheumNow (  View Tweet)
Full read review of the benefits & impact of hydroxychloroquine in #SLE. Benefits on: - T cells, cytokines, TLR signaling - VTE prevention - Decr CV risks - Glucose & lipid benefits - Pregnancy https://t.co/bio9cYCIeb https://t.co/zfyUBaecbu
Dr. John Cush @RheumNow (  View Tweet)
Brazilian Registry of Spondyloarthritis study of 1096 SpA pts, found 73% HLA-B27 positivity. B27+ signif assoc w/ males, earlier onset/Dx, uveitis, +FHx. B27 negativity assoc w/ psoriasis, higher peripheral arthritis/disease activity, worse QOL, mobility https://t.co/OUOVozdoXw https://t.co/z8hhPjRUfx
Dr. John Cush @RheumNow (  View Tweet)
Small-molecule Drugs to Treat Systemic Lupus Erythematosus A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs. https://t.co/LKLUT8kLSk https://t.co/1SbUbiCpYs
Dr. John Cush @RheumNow (  View Tweet)

No Great Options for Treating VEXAS

MedPage Today

For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.

Read Article
Window of Opportunity in Psoriatic Arthritis The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome. https://t.co/eUL1wzrXVt https://t.co/XSETW2zpGs
Dr. John Cush @RheumNow (  View Tweet)
Research presented at DDW 2024 demonstrated the superiority of guselkumab over ustekinumab or placebo in 1,021 patients with moderately to severely active Crohn's disease enrolled in the phase III GALAXI 2 and GALAXI 3 trials https://t.co/HdZf24Twsq https://t.co/REeAAskpX5
Dr. John Cush @RheumNow (  View Tweet)
DRESS - Drug Reaction With Eosinophilia and Systemic Symptoms - review on JAMA. Common drugs include allopurinol, Bactrim, Minocin, etc. https://t.co/1DmgyX33Cl

Dr. John Cush @RheumNow (  View Tweet)

Biomarkers Predictive of a Deucravacitinib Response in Psoriatic Arthritis

A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.

Read Article

Lupus Research Alliance Grants for Lupus Innovation

EurekAlert!

The Lupus Research Alliance (LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA). They will conduct innovative research to uncover the underlying mechanisms and identify novel targets and pathways that could be harnessed to predict, monitor, and treat lupus, a complex autoimmune disease.

Read Article
No Link Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance Annals of Internal Medicine reports a study of more than 75,000 persons screened for MGUS and found no association between AIRD and MGUS. https://t.co/cTuIWU7eoa https://t.co/78kQvBGVzs
Dr. John Cush @RheumNow (  View Tweet)
SLE Cost of Care and Disease Activity A longitudinal, multinational study shows that SLE patients achieving remission or low disease activity incur lower overall direct/indirect (DCs, ICs) healthcare costs than those with persistent activity. https://t.co/Rk7SNpHaKu https://t.co/yvJ4qw1YCJ
Dr. John Cush @RheumNow (  View Tweet)
Lille Univ Hosp study of 485 systemic sclerosis pts, found osteoporosis in 23% (18% w/ fragility Fx). OP independently linked to age (OR1.06), topoisomerase I Ab+ positivity (OR 2.22) & GC treatment (OR 4.48) https://t.co/9KN5VQnl4A https://t.co/L7RwDdzaFZ
Dr. John Cush @RheumNow (  View Tweet)
Greek cohort study of 570 SLE pts; lupus nephritis was initial presentation in 59, w/ another 66 LN during F/U (total LN= 22%). Predictors of LN: male sex (adjHR 4.31), Dx age <26yrs (3.71), Hi dsDNA (2.48), low C3/C4 (NS 2.24) https://t.co/lGmZlBpaPq https://t.co/XLqODDTnX6
Dr. John Cush @RheumNow (  View Tweet)
"Don't You Know Who I am?" (5.17.2024) Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis? https://t.co/oH5qdTvGY9 https://t.co/gTqIKemvOu
Dr. John Cush @RheumNow (  View Tweet)
Australian multicenter KARAOKE RCT of 262 adults w/ Knee OA (w/ MRI effusion/synovitis) Rx w/ placebo vs , 2 g/d of krill oil showed no significant benefit in pain VAS score, −19.9 [krill oil] vs −20.2 [placebo]. https://t.co/8QSZyzIVh9 https://t.co/WbSb2gcmHb
Dr. John Cush @RheumNow (  View Tweet)